Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
Menon · 2025 · Nature Medicine
What this paper found
Phase 2 trial of VE303, a defined consortium of 8 human commensal bacterial strains, for recurrent C. difficile infection. 80% reduction in recurrence vs placebo; primary endpoint met; Phase 3 planned.
Why this is on the map
Not yet tested in autoimmune conditions, but proof-of-concept that defined multi-strain consortia work as a therapeutic modality. Watch this space for AS.
On the map under this thread
DOI: 10.1038/s41591-024-03337-4· opens in a new tab. The full paper is on the publisher’s site, not here.
Related papers on the board
Papers sharing one or more threads with this one.
HLA-B27-associated gut microbiota and amino acid perturbations promote ankylosing spondylitis through M1 macrophage activation
Gut Microbes
Shows that HLA-B27, the gene most strongly linked to AS, reshapes which bacteria live in the gut and how the body handles certain amino acids, which in turn activates the inflammatory immune cells driving the disease. Suggests targeting the gut and these metabolic changes could become a real treatment route.
Gut microbiota and ankylosing spondylitis: current insights and future challenges
Microbial Cell
Comprehensive review of how gut bacterial imbalance disrupts the IL-23/IL-17 inflammatory pathway and weakens the intestinal barrier in AS. Identifies the lack of standardised methodology and large cohorts as the bottleneck for translating this into treatments.
Dysbiosis of Gut Microbiota in Ankylosing Spondylitis Patients
Dove Medical Press
Confirms that intestinal dysfunction precedes or amplifies systemic inflammation in AS. Frames gut microbiota as the convergence point where genetic, immune, and microbial factors meet.
The role of gut microbiota in autoimmune disease progression and therapy: a comprehensive synthesis
Frontiers in Microbiomes
Review and meta-analysis of dysbiosis across rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. Identifies bidirectional gut-immune interactions via mucosal modulation and T-regulatory cell activity.